Cybin (TSE:CYBN) has released an update.
Cybin Inc. has announced plans to launch a Phase 3 clinical trial in late summer 2024 for CYB003, a potential new treatment for Major Depressive Disorder (MDD), following a successful initial meeting with the FDA. The trial will involve 30 clinical sites across the US and Europe, and will include strategies to minimize functional unblinding. Additionally, the company is set to release 12-month Phase 2 efficacy data for CYB003 by the end of 2024.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
